Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Community Genetics and Dignity in Diversity in the Quebec Network of Genetic Medicine

Scriver C.R.

Author affiliations

Departments of Biology, Human Genetics, and Pediatrics, Faculties of Science and Medicine, McGill University, Montreal, Canada

Related Articles for ""

Community Genet 2006;9:142–152

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: June 02, 2006
Issue release date: May 2006

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 1662-4246 (Print)
eISSN: 1662-8063 (Online)

For additional information: https://www.karger.com/PHG

Abstract

The Quebec Network of Genetic Medicine (QNGM), implemented in 1971, has been an integrated program of community genetics serving the population (approximately 7.5 million) of Quebec province in Canada. QNGM reported to the Minister of Social Affairs and operated under an umbrella of universal health insurance in the province. The Network’s programs have been run by members of the four university medical schools of the province under the direction of a central committee. A global annual budget was awarded to QNGM from its inception. Among its many programs, QNGM supported: (1) two newborn screening programs (using blood and urine samples) for early diagnosis, treatment and research in phenylketonuria, hereditary tyrosinemia, congenital hypothyroidism, and in a large number of other hereditary metabolic diseases; (2) follow-up of confirmatory diagnostic tests at regional centers, followed by supervision of ambulatory treatment modalities; (3) carrier screening and reproductive counseling for Tay-Sachs and β-thalassemia diseases; (4) a spectrum of feasibility (research) studies (e.g., screening for biotinidase deficiency, neuroblastoma, hemoglobinopathies, and cystic fibrosis) to inform policy decisions. QNGM performed economic analyses of its major programs and followed prevailing ethical guidelines. Its global budget and integrated structure terminated in 1994, although some of its programs continue independently.

© 2006 S. Karger AG, Basel


References

  1. Scriver CR: Human genes: determinants of sick populations and sick patients. Can J Public Health 1988;79:222–224.
  2. Lalonde M: A new perspective on the health of Canadians. A working document. Ottawa, Government of Canada, 1974.
  3. Modell B, Kuliev AM: Services for thalassaemia as a model for cost-benefit analysis of genetic services. J Inherit Metab Dis 1991;14:640–651.
  4. Laberge C, Scriver CR, Clow CL, Dufour D: Le Réseau de Médecine Génétique du Québec: un programme intégré de diagnostic, counseil et traitement des maladies métaboliques héréditaire. Union Med Can 1975;104:428–432.
  5. Scriver CR, Laberge C, Clow CL, Fraser FC: Genetics and medicine: an evolving relationship. Science 1978;200:946–952.
  6. Charbonneau M, Laberge C, Scriver CR, Dussault JH, Lemieux B, Melançon S: The Quebec Network of Genetic Medicine. Can J Public Health 1987;78:79–83.
  7. National Academy of Sciences: Genetic Screening. Programs, Principles and Research. Washington, National Research Council, 1975.
  8. Scriver CR: Human genetics: lessons from Quebec population(s). Annu Rev Genomics Hum Genet 2001;2:69–101.
  9. Fix A: Migration and Colonization in Human Microevolution. New York, Cambridge University Press, 1999.
  10. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, Mitchell GA: Historical founder effects and their impact on medical genetics in Quebec. Clin Genet 2005;68:287–301.
    External Resources
  11. Arrow KJ: Theoretical issues in health insurance; in Arrow KJ (ed): Collected Papers of Kenneth J. Arrow. Cambridge, Belknap Press of Harvard University Press, 1985, pp 208–233.
  12. Gori GB, Richter BJ: Macroeconomics of disease prevention in the United States. Science 1978;200:1124–1130.
  13. Wilson JMG, Jungner G: Principles and Practice of Screening for Disease. Public Health Papers No 34. Geneva, WHO, 1968.
  14. US Congress: Cystic Fibrosis and DNA Tests: Implications of Carrier Screening. Washington, US Government Printing Office, 1992.
  15. Institute of Medicine: Assessing Genetic Risks. Implications for Health and Social Policy. Washington, National Academy Press, 1994.
  16. Clow C, Scriver CR, Davies E: Results of mass screening for hyperaminoacidemias in the newborn infant. Am J Dis Child 1969;117:48–53.
  17. Lemieux C, Auray-Blais C, Giguère R, Shapcott D, Scriver CR: Newborn urine screening experience with over one million infants in the Quebec Network of Genetic Medicine. J Inherit Metab Dis 1988;11:45–55.
  18. Clow CL, Reade TM, Scriver CR: Management of hereditary metabolic disease. The role of allied health personnel. N Engl J Med 1971;284:1292–1298.
  19. Clow CL, Ishmael H, Scriver CR, Murray K, Campeau H, Long D, Steinberg HA: The National Food Distribution Centre for Management of Patients with Hereditary Metabolic Disease. Bull Genet Soc Can 1975;6:29–31.
  20. Scriver CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, Novak J, Teebi S, Nowacki PM: PAHdb: a locus-specific knowledgebase. Hum Mutat 2000;15:99–104.
  21. Carter KC, Byck S, Waters PJ, Richards B, Nowacki PM, Laframboise R, Lambert M, Treacy E, Scriver CR: Mutation at the phenylalanine hydroxylase gene (PAH) and its use to document population genetic variation: the Quebec experience. Eur J Hum Genet 1998;6:61–70.
  22. Byck S, Morgan K, Blanc L, Scriver CR: The PAH locus and population genetic variation: the Quebec example (abstract). Am J Hum Genet 1996;59:A33.
  23. Dagenais DL, Courville L, Dagenais MG: A cost-benefit analysis of the Quebec Network of Genetic Medicine. Soc Sci Med 1985;20:601–607.
  24. Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K: The GM2 gangliosidoses; in Scriver CR, Beaudet AL, Sly SW, Valle D, Childs B, Kinzler KW, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 3827–3876.
  25. Kaplan F, Scriver CR: Tay-Sachs disease; in Wald N, Lech I (eds): Antenatal and Neonatal Screening, ed 2. Oxford, Oxford University Press, 2000, pp 139–158.
  26. Okada S, O’Brien JS: Tay-Sachs disease: generalized absence of a β-D-N-acetylhexosaminidase component. Science 1969;165:698–700.
  27. Delvin E, Pottier A, Scriver CR, Gold RJM: The application of an automated hexosaminidase assay to genetic screening. Clin Chim Acta 1974;53:135–142.
  28. Gold RJM, Maag UR, Neal JL, Scriver CR: The use of biochemical data in screening for mutant alleles and in genetic counselling. Ann Hum Genet 1974;37:315–326.
  29. Beck E, Blaichman S, Scriver CR, Clow C: Advocacy and compliance in genetic screening. Behavior of physicians and clients in a voluntary program of testing for the Tay-Sachs gene. N Engl J Med 1974;291:1166–1170.
  30. Mitchell J, Capua A, Clow C, Scriver CR: Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 1996;59:593–598.
  31. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zieger K: Tay-Sachs disease: carrier screening, prenatal diagnosis, and the molecular era. JAMA 1993;270:2307–2315.
  32. Broide E, Zeigler M, Eckstein J, Bach G: Screening for carriers of Tay-Sachs disease in the ultra-Orthodox Ashkenazi Jewish community in Israel. Am J Med Genet 1993;47:213–215.
  33. Weatherall DJ, Clegg JB, Higgs DR, Wood WG: The hemoglobinopathies; in Scriver CR, Beaudet AL, Sly SW, Valle D, Childs B, Kinzler KW, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 4571–4636.
  34. Scriver CR, Bardanis M, Cartier L, Clow CL, Lancaster GA, Ostrowsky JT: Beta-thalassemia disease prevention: genetic medicine applied. Am J Hum Genet 1984;36:1024–1038.
  35. Tannis-Hadjopoulos M, Gold RJM, Maag UR, Metrakos JD, Scriver CR: Improved detection of beta-thalassaemia carriers by a two-test method. Hum Genet 1977;38:315–324.
    External Resources
  36. Fernandes MJG, Kaplan F, Clow CL, Hechtman P, Scriver CR: Specificity and sensitivity of hexosaminidase assays and DNA analysis for the detection of Tay-Sachs disease gene carriers among Ashkenazi Jews. Genet Epidemiol 1992;9:169–175.
  37. Kaplan F, Kokotsis G, Capua A, Scriver CR: Quantitation of beta-thalassemia genes in Quebec immigrants of Mediterranean, Southeast Asian, and Asian Indian origins. Clin Invest Med 1991;14:325–330.
  38. Andermann E, Andermann F, Patry G, Lafontaine R, Geoffroy G, Scriver CR, Wolfe L: Tay-Sachs disease in Quebec: evidence for a geographic aggregate in the French-Canadian population and identification of a new retardation syndrome with possible linkage to the Tay-Sachs gene. Trans Am Neurol Assoc 1973;98:17–21.
  39. Andermann E, Scriver CR, Wolfe LS, Dansky L, Andermann F: Genetic variants of Tay-Sachs disease: Tay-Sachs disease and Sandhoff’s disease in French Canadians, juvenile Tay-Sachs disease in Lebanese Canadians and a Tay-Sachs screening program in the French-Canadian population. Prog Clin Biol Res 1977;18:161–188.
  40. Myerowitz R, Hogikyan ND: A deletion involving Alu sequences in the beta-hexosminidase alpha-chain gene of French Canadians with Tay-Sachs disease. J Biol Chem 1987;262:15396–15399.
  41. De Braekeleer M, Hechtman P, Andermann E, Kaplan F: The French Canadian Tay-Sachs disease deletion mutation: identification of probable founders. Hum Genet 1992;89:83–87.
  42. Hechtman P, Kaplan F, Bayleran J, Boulay B, Andermann E, De Braekeleer M, Melançon S, Lambert M, Potier M, Gagne R, Kolodny E, Clow C, Capua A, Prevost C, Scriver C: More than one mutant allele causes infantile Tay-Sachs disease in French-Canadians. Am J Hum Genet 1990;47:815–822.
  43. Rioux E, Delage JM: Thalassemie au Québec. Union Med Can 1964;93:1086–1089.
  44. Desjardins L, Rousseau C, Duplain JM, Vallet JP, Auger P: La thalassemie chez les Quebecois Francophones. Can Med Assoc J 1978;199:709–713.
  45. Kaplan F, Kokotsis G, De Braekeleer M, Morgan K, Scriver CR: Beta-thalassemia genes in French-Canadians: haplotype and mutation analysis of Portneuf chromosomes. Am J Hum Genet 1990;46:126–132.
  46. Prevost C, Laframboise R, Bardanis M, Clow C, Lancaster G, Desjardins L, Cantin F, Scriver CR: La gène de la beta-thalassémie au Canada Français: relance dans le comté de Portneuf. Union Med Can 1988;118:242–244.
  47. Martino T, Kaplan F, Diamond S, Oppenheim A, Scriver CR: Probable identity by descent and discovery of familial relationships by means of a rare beta-thalassemia haplotype. Hum Mutat 1997;9:86–87.
  48. Oppenheim A, Oron V, Filon D, Fearon CC, Rachmilewitz EA, Kazazian HH Jr, Rund D: Sporadic alleles, including a novel mutation, characterize beta-thalassemia in Ashkenazi Jews. Hum Mutat 1993;2:155–157.
  49. Daigneault J, Aubin G, Simard F, De Braekeleer M: Genetic epidemiology of cystic fibrosis in Saguenay-Lac-St-Jean (Quebec, Canada). Clin Genet 1991;40:298–303.
  50. Kaplan F, Clow C, Scriver CR: Cystic fibrosis carrier screening by DNA analysis: a pilot study of attitudes among participants. Am J Hum Genet 1991;49:240–242.
  51. Mitchell J, Scriver CR, Clow C, Kaplan F: What young people think and do when the option for cystic fibrosis carrier testing is available. J Med Genet 1993;30:538–542.
  52. Yorke D, Mitchell J, Clow C, Nuguid E, Cadogan R, Sinclair D, Luscombe S, Rozen R, Meredith P, Esseltine D, Scriver CR: Newborn screening for sickle cell and other hemoglobinopathies: a Canadian pilot study. Clin Invest Med 1992;15:376–383.
  53. Scriver CR: Genetic screening: implications for preventive medicine. Am J Pub Health 1983;73:243–245.
  54. Dunkel G, Scriver CR, Clow CL, Melançon S, Lemieux B, Grenier A, Laberge C: Prospective ascertainment of complete and partial serum biotinidase deficiency in the newborn. J Inherit Metab Dis 1989;12:131–138.
  55. Scriver CR, Gregory D, Bernstein M, Clow CL, Weisdorf T, Dougherty GE, Auray-Blais C, Giguère R, Lemieux B, Laberge C: Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec. Can Med Assoc J 1987;136:952–956.
  56. Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robisson L, Shuster J, Byrne T, Gregory D, Hill G, Dougherty G, Scriver C, Lemieux B, Tuchman M, Woods WG: A population-based study of neuroblastoma incidence, survival and mortality in North America. J Clin Oncol 1992;10:323–329.
  57. Woods WG, Gao RN, Shuster JJ, Robisson LL, Bernstein M, Weitzman S, Bunin G, Levy I, Brossard J, Dougherty G, Tuchman M, Lemieux B: Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346:1041–1046.
  58. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, Klein G, Sander J, Schwartz K, Treuner J, Zorn U, Michaelis J: Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047–1053.
  59. Cunningham G: The science and politics of screening newborns. N Engl J Med 2002;346:1084–1085.
    External Resources
  60. Mitchell GA, Grompe M, Lambert M, Tanguay RM: Hypertyrosinemia; in Scriver CR, Beaudet AL, Sly SW, Valle D, Childs B, Kinzler KW, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 1777–1805.
  61. Scriver CR: Book review. Assessing Genetic Risks: Implications for Health and Social Policy. Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG. Washington, National Academy Press, 1994. Am J Hum Genet 1995;56:814–816.
  62. McCabe L: Efficacy of a targeted genetic screening program for adolescents. Am J Hum Genet 1996;59:762–763.
  63. Motulsky AG: Screening for genetic diseases. N Engl J Med 1997;336:1314–1316.
  64. Dussault JH, Morissette J, Letarte J, Guyda H, Laberge C: Thyroxine-binding globulin capacity and concentration evaluated from blood spots on filter paper in a screening program for neonatal hypothyroidism. Clin Chem 1980;26:463–465.
  65. Wilcken B, Wiley V, Hammond J, Carpenter K: Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003;23:2304–2312.
    External Resources
  66. Ostrowsky JT, Lippman A, Scriver CR: Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health 1985;56:814–816.
  67. Evans RG: ‘We’ll take care of it for you.’ Health care in the Canadian community. Daedalus 1988;117:155–189.
  68. Knoppers BM, Chadwick R: The human genome project: under an international ethical microscope. Science 1994;265:2035–2036.
  69. American Society of Human Genetics Board of Directors/American Council of Medical Genetics Board of Directors: Points to consider: ethical, legal, and psychological implications of genetic testing in children and adolescents. Am J Hum Genet 1995;57:1233–1241.
  70. Science Council of Canada: Genetics in Canadian Health Care. Science Council of Canada. Report No 42, i-xi-1-132. Ottawa, Ministry of Supply and Services, Government of Canada, 1991.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: June 02, 2006
Issue release date: May 2006

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 1662-4246 (Print)
eISSN: 1662-8063 (Online)

For additional information: https://www.karger.com/PHG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.